1. Wolfe F (1996) The natural history of rheumatoid arthritis. J Rheumatol Suppl 44: 13–22
2. Rojkovich B and Poór G (2002) Prognostic factors in rheumatoid arthritis [Hungarian]. Orv Hetil 143: 2019–2026
3. FDA (1997) Guidance for industry: clinical development programs for drugs, devices and biological products for the treatment of rheumatoid arthritis (RA) [
http://www.fda.gov/cber/gdlns/rheumcln.pdf
] (accessed 15 October 2008)
4. Boers M et al. (1994) World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol Suppl 41: 86–89
5. Boers M et al. (1995) Assessing the activity of rheumatoid arthritis. Baillieres Clin Rheumatol 9: 305–317